PO Box 1488
Warrenville, IL 60555
Phone: 331.248.7888
Email: sidp@affinity-strategies.com
Drs. Emily Kirkpatrick, Paul Sax, and Jill Strayer join Dr. Rachel Britt to discuss their experiences using injectable long-acting antiretrovirals, especially cabotegravir/rilpivirine, in their clinics. Listen to learn not only about logistical challenges with these drugs, but also creative solutions to overcome them.
Emily Kirkpatrick, Pharm.D., BCIDP, AAHIVP
Emily Kirkpatrick is a clinical pharmacy specialist in infectious disease at University Health San Antonio, Texas. Her practice interests include HIV, opportunistic infections, antimicrobial stewardship, and transitions of care. She completed her PGY-1 at Parkland Health in Dallas, Texas and her PGY-2 in infectious disease at University Health in San Antonio.
Paul Sax, MD
Dr. Paul Sax is is Clinical Director of the Division of Infectious Diseases at Brigham and Women’s Hospital and Professor of Medicine at Harvard Medical School. He is actively involved in HIV research, clinical practice, and teaching. His research interests include clinical trials of new antiretroviral therapies, the cost-effectiveness of HIV management strategies, and the complications of antiretroviral treatment. Dr. Sax is Principal Investigator of the Brigham and Women’s Hospital AIDS Clinical Trials Unit and a member of the Cost Effectiveness of Preventing AIDS Complications (CEPAC) Research Group.
Jill Strayer, PharmD, BCPS
Jill Strayer is a clinical pharmacist at the University of Wisconsin Health. Her practice interests include HIV, pediatric ID, stewardship, long-acting HIV injectable medication coordination, and primary care optimization. She attended pharmacy School at the University of Iowa and did her PGY-1 Residency at the University of Wisconsin Health.
